Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.
Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Dr Reddy's Labs reports 9.5 percent fall in consolidated net profit after tax to Rs 1342 crore in Q2
Indian generic drugmaker Dr Reddy's Laboratories recorded a 9.5 percent decline in its consolidated net profit after tax to Rs 13.42 billion (USD 159.6 million) for the quarter ended September
Dr Reddy's Labs Q2 Preview: Healthy double-digit revenue growth seen, but PAT may fall
For the July-September 2024 period, net profit is expected to decline by 3% year-on-year, based on the average estimate from four brokerages. Sales, however, are projected to increase by 13% year-on-year,
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
MarketWatch8h
Dr. Reddy's Laboratories outperforms competitors on strong trading day
Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...
Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...
ndtvprofit8h
Dr Reddy's Aims To Consistently Deliver Double-Digit Sales Growth, Ebitda Margin Of 25%
Dr Reddy's expects overall sales to grow in double digits, with branded business in India and emerging markets growing in ...
cnbctv1815h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Business Insider14h
Dr. Reddy’s Reports Strong Q2FY25 Results and Strategic Expansions
Dr. Reddy’s Laboratories Ltd ( (RDY)) has released its Q2 earnings. Here is a breakdown of the information Dr. Reddy’s Laboratories Ltd presented to its investors. Dr. Reddy’s ...
Neutral Dr Reddys Laboratories; target of Rs 1390: Motilal Oswal
Motilal Oswal recommended Neutral rating on Dr Reddys Laboratories with a target price of Rs 1390 in its research report ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
Dr Reddy’s Financials Verified; Investor Confidence Boosted
Dr Reddy’s Laboratories (RDY) has released an update. Dr Reddy’s Laboratories’ recent financial review by Ernst & Young ...